{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T23:20:20Z","timestamp":1775863220322,"version":"3.50.1"},"reference-count":35,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Parathyroid hormone (PTH) assays are not standardized and therefore PTH results\n                    are interpreted using manufacturer-provided assay-specific reference intervals.\n                    Assay-specific PTH reference intervals, however, do not account for\n                    between-assay differences and lead to discordance in the diagnosis of\n                    normocalcaemic primary hyperparathyroidism (NCPHPT). PTH increases with age\n                    independent of vitamin D, renal function, phosphate and ionized calcium. The\n                    observed variations in age-nonspecific PTH reference intervals may, in part, be\n                    attributed to the varying proportions of individuals from different age sub-sets\n                    included in the direct sampling reference interval studies. We assessed the\n                    impact of recently derived age-specific reference intervals for Abbott and Roche\n                    PTH assays on the diagnosis and diagnostic concordance of previously identified\n                    NCPHPT individuals. Of the 46 NCPHPT individuals identified using elevated\n                    Abbott PTH, only 16 (35%) were concordant for NCPHPT whereas 30 (65%) had normal\n                    PTH when samples were analysed by the Roche method and results were interpreted\n                    using the manufacturer-provided reference intervals for both methods. However,\n                    interpreting results using the method-specific age-related PTH reference\n                    intervals resulted in 31 (67%) individuals having a concordant normal PTH, eight\n                    (17%) having concordant NCPHPT and only seven (15%) remaining discordant (NCPHPT\n                    by Abbott and normal by Roche methods). Application of assay- and age-specific\n                    reference intervals decreases the diagnosis of NCPHPT and improves diagnostic\n                    concordance between PTH assays. We suggest that the diagnosis of NCPHPT should\n                    be based on assay- and age-specific PTH reference intervals. Until PTH assays\n                    are harmonized, subsequent PTH measurements for NCPHPT patients should ideally\n                    be performed using the same assay.<\/jats:p>","DOI":"10.1055\/a-2690-6416","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T22:40:01Z","timestamp":1757371201000},"page":"471-476","source":"Crossref","is-referenced-by-count":1,"title":["The Application of Assay- and Age-Specific Parathyroid Hormone (PTH)\n                    Reference Intervals Decreases the Diagnosis of Normocalcaemic Primary\n                    Hyperparathyroidism and Improves Diagnostic Concordance of PTH\n                    Assays"],"prefix":"10.1055","volume":"57","author":[{"given":"Halimah","family":"Khalil","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry, The Royal Wolverhampton NHS\n                    Trust, Black Country Pathology Services, Wolverhampton, United Kingdom of Great\n                    Britain and Northern Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2064-9432","authenticated-orcid":false,"given":"Jonathan","family":"Fenn","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry, The Royal Wolverhampton NHS\n                    Trust, Black Country Pathology Services, Wolverhampton, United Kingdom of Great\n                    Britain and Northern Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Sanders","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry, The Royal Wolverhampton NHS\n                    Trust, Black Country Pathology Services, Wolverhampton, United Kingdom of Great\n                    Britain and Northern Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Ford","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry, The Royal Wolverhampton NHS\n                    Trust, Black Country Pathology Services, Wolverhampton, United Kingdom of Great\n                    Britain and Northern Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7483-9253","authenticated-orcid":false,"given":"Rousseau","family":"Gama","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry, The Royal Wolverhampton NHS\n                    Trust, Black Country Pathology Services, Wolverhampton, United Kingdom of Great\n                    Britain and Northern Ireland"},{"name":"School of Medicine and Clinical Practice, University of\n                    Wolverhampton, Wolverhampton, United Kingdom of Great Britain and Northern\n                    Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1306-8832","authenticated-orcid":false,"given":"Tejas","family":"Kalaria","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry, The Royal Wolverhampton NHS\n                    Trust, Black Country Pathology Services, Wolverhampton, United Kingdom of Great\n                    Britain and Northern Ireland"},{"name":"School of Medicine and Clinical Practice, University of\n                    Wolverhampton, Wolverhampton, United Kingdom of Great Britain and Northern\n                    Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0140-6736(17)31430-7","article-title":"Hyperparathyroidism","volume":"391","author":"J P Bilezikian","year":"2018","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1210\/jc.2012-4022","article-title":"Incidence and prevalence of primary hyperparathyroidism in a racially mixed\n                    population","volume":"98","author":"M W Yeh","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jbmr.4677","article-title":"Evaluation and management of primary hyperparathyroidism: summary statement and\n                    guidelines from the fifth international workshop","volume":"37","author":"J P Bilezikian","year":"2022","journal-title":"J Bone Miner Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e10391","DOI":"10.1002\/jbm4.10391","article-title":"Normocalcemic hyperparathyroidism: a heterogeneous disorder often\n                    misdiagnosed?","volume":"4","author":"G Zavatta","year":"2020","journal-title":"JBMR Plus"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1210\/clinem\/dgaa084","article-title":"Normocalcemic hyperparathyroidism: study of its prevalence and natural\n                    history","volume":"105","author":"M Schini","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.beem.2018.09.009","article-title":"Management of normocalcemic primary hyperparathyroidism","volume":"32","author":"N E Cusano","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1530\/EC-15-0030","article-title":"Normocalcemic primary hyperparathyroidism: a survey in a small village of\n                    Southern Italy","volume":"4","author":"E Vignali","year":"2015","journal-title":"Endocr Connect"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s12020-012-9694-z","article-title":"Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred\n                    postmenopausal women","volume":"42","author":"A Garc\u00eda-Mart\u00edn","year":"2012","journal-title":"Endocrine"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/cen.12819","article-title":"Normocalcaemic, vitamin D-sufficient hyperparathyroidism \u2013 high prevalence and\n                    low morbidity in the general population: a long-term follow-up study, the WHO\n                    MONICA project, Gothenburg, Sweden","volume":"83","author":"G Kontogeorgos","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1055\/a-1856-4900","article-title":"The diagnosis of normocalcaemic hyperparathyroidism is strikingly dissimilar\n                    using different commercial laboratory assays","volume":"54","author":"T Kalaria","year":"2022","journal-title":"Horm Metab Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"bvae004","DOI":"10.1210\/jendso\/bvae004","article-title":"Age-specific reference intervals of Abbott intact PTH-potential impacts on\n                    clinical care","volume":"8","author":"T Kalaria","year":"2024","journal-title":"J Endocr Soc"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1210\/jc.2014-1414","article-title":"Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth\n                    international workshop","volume":"99","author":"R Eastell","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cca.2016.10.016","article-title":"Perspective and priorities for improvement of parathyroid hormone (PTH)\n                    measurement \u2013 a view from the IFCC working group for PTH","volume":"467","author":"C M Sturgeon","year":"2017","journal-title":"Clin Chim Acta"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40618-016-0553-2","article-title":"How the reference values for serum parathyroid hormone concentration are (or\n                    should be) established?","volume":"40","author":"J-C Souberbielle","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"Clinical practice guideline update for the diagnosis, evaluation, prevention,\n                    and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"7","author":"KDIGO","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"ref16","first-page":"494","article-title":"Influence of vitamin D on parathyroid function in the elderly","volume":"75","author":"J M Quesada","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1172\/JCI111995","article-title":"Evidence for alteration of the vitamin D-endocrine system in blacks","volume":"76","author":"N H Bell","year":"1985","journal-title":"J Clin Invest"},{"key":"ref18","first-page":"176","article-title":"Evidence of an age-related decrease in intestinal responsiveness to vitamin D:\n                    relationship between serum 1,25-dihydroxyvitamin D3 and intestinal vitamin D\n                    receptor concentrations in normal women","volume":"75","author":"P R Ebeling","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1056\/NEJM198108133050704","article-title":"Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic\n                    patients","volume":"305","author":"D M Slovik","year":"1981","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e10517","DOI":"10.1002\/jbm4.10517","article-title":"Renal contributions to age-related changes in mineral metabolism","volume":"5","author":"D L Irsik","year":"2021","journal-title":"JBMR Plus"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.arr.2012.06.001","article-title":"Age-related changes in the response of intestinal cells to 1\u03b1,25(OH)2-vitamin\n                    D3","volume":"12","author":"V Gonzalez Pardo","year":"2013","journal-title":"Ageing Res Rev"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/ajcn\/80.4.998","article-title":"Effect of age on calcium absorption in postmenopausal women","volume":"80","author":"BE C Nordin","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1210\/jc.2014-4370","article-title":"Brief report: does PTH increase with age, independent of 25-hydroxyvitamin D,\n                    phosphate, renal function, and ionized calcium?","volume":"100","author":"S J Carrivick","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1530\/EJE-15-0595","article-title":"Serum PTH reference values established by an automated third-generation assay in\n                    vitamin D-replete subjects with normal renal function: consequences of\n                    diagnosing primary hyperparathyroidism and the classification of dialysis\n                    patients","volume":"174","author":"J-C Souberbielle","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s40618-023-02107-2","article-title":"Big data-based parathyroid hormone (PTH) values emphasize need for age\n                    correction","volume":"46","author":"LBC P Cavalcante","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/cen.13486","article-title":"Parathyroid hormone: data mining for age-related reference intervals in\n                    adults","volume":"88","author":"C-JL Farrell","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e23771","DOI":"10.1002\/jcla.23771","article-title":"Stability and validity of intact parathyroid hormone levels in different sample\n                    types and storage conditions","volume":"35","author":"H Khalil","year":"2021","journal-title":"J Clin Lab Anal"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1210\/jc.2013-1300","article-title":"Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based\n                    nonreferral populations","volume":"98","author":"N E Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1210\/jc.2002-021404","article-title":"Normocalcemic primary hyperparathyroidism: evidence for a generalized\n                    target-tissue resistance to parathyroid hormone","volume":"88","author":"G Maruani","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"dgaa174","DOI":"10.1210\/clinem\/dgaa174","article-title":"Clinical, biochemical, and radiological profile of normocalcemic primary\n                    hyperparathyroidism","volume":"105","author":"A Palermo","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1515\/cclm-2013-0315","article-title":"Sampling and storage conditions influencing the measurement of parathyroid\n                    hormone in blood samples: a systematic review","volume":"51","author":"E A Hanon","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"ref33","first-page":"3453","article-title":"Impact of variation between assays and reference intervals in the diagnosis of\n                    endocrine disorders","volume":"13","author":"N Lorde","year":"2023","journal-title":"Diagnostics (Basel, Switzerland)"},{"key":"ref34","first-page":"3086","article-title":"Vitamin D status and redefining serum parathyroid hormone reference range in the\n                    elderly","volume":"86","author":"J C Souberbielle","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4158\/EP.12.2.137","article-title":"Reference range for serum parathyroid hormone","volume":"12","author":"J F Aloia","year":"2006","journal-title":"Endocr Pract"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1210\/jc.2008-1758","article-title":"Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third\n                    international workshop","volume":"94","author":"R Eastell","year":"2009","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2690-6416.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T22:53:45Z","timestamp":1758236025000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2690-6416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":35,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2025,9,18]]},"published-print":{"date-parts":[[2025,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2690-6416","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}